Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pevonedistat and azacitidine in MDS or MDS/MPN after DNMTi failure
NCT03238248Phase 2Completed
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Aug 2017
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pevonedistat in myelodysplastic syndrome (MDS), myelodysplastic/myeloproliferative neoplasm (MDS/MPN), sponsored by Vanderbilt-Ingram Cancer Center. Started Aug 2017; status: completed.
02
Drugs
pevonedistat
03
Conditions
myelodysplastic syndrome (MDS)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on NCT03238248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03238248.